Hepatitis B and C Diagnostics Market is estimated to increase at a growth rate of 5.2% CAGR over the forecast period from 2024 to 2030.
The global Hepatitis B and C Diagnostics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Immunodiagnostics, NAT), By Disease (Hepatitis B, Hepatitis C).
An Introduction to Hepatitis B and C Diagnostics Market in 2024
The Hepatitis B and C Diagnostics Market encompasses diagnostic tools, laboratory tests, and screening methods used for the detection, monitoring, and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. This market includes serology tests, nucleic acid tests (NAT), viral load quantification assays, and imaging techniques aimed at identifying viral markers, assessing liver function, and guiding treatment decisions for patients with hepatitis B or C. Advancements in hepatitis diagnostics focus on rapid testing technologies, point-of-care devices, and molecular assays for accurate and timely disease detection and monitoring.
Hepatitis B and C Diagnostics Market Competitive Landscape
The global Hepatitis B and C Diagnostics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Hepatitis B and C Diagnostics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Hepatitis B and C Diagnostics Industry include- Bio Rad Laboratories Inc, bioMerieux SA, DAAN Gene Co. Ltd, DiaSorin SpA, Enzo Biochem Inc, F. Hoffmann La Roche Ltd, Grifols S.A., Hologic Inc, MedMira Inc, OraSure Technologies Inc, PerkinElmer Inc, QIAGEN N.V., Quidel Corp, Randox Laboratories Ltd, Siemens AG, Sysmex Corp, Xiamen Innovax Biotech Co. Ltd.
Hepatitis B and C Diagnostics Market Trend: Advancements in Point-of-Care Testing Technologies
A significant trend in the hepatitis B and C diagnostics market is the advancements in point-of-care testing (POCT) technologies. Traditional diagnostic methods for hepatitis B and C infections often involve laboratory-based tests that require specialized equipment and trained personnel, leading to delays in diagnosis and treatment initiation. However, there is a growing demand for rapid and decentralized testing solutions that can deliver timely results at the point of care, particularly in resource-limited settings and underserved communities. Manufacturers are developing innovative POCT devices that offer rapid detection of hepatitis B and C viruses from small sample volumes, enabling prompt diagnosis, linkage to care, and appropriate management strategies. This trend towards POCT technologies reflects a shift towards patient-centered healthcare delivery and the importance of early diagnosis in preventing disease transmission and improving patient outcomes.
Hepatitis B and C Diagnostics Market Driver: Increasing Global Burden of Hepatitis B and C Infections
A primary driver propelling the hepatitis B and C diagnostics market is the increasing global burden of hepatitis B and C infections. Hepatitis B and C viruses are major causes of chronic liver disease, leading to serious complications such as cirrhosis, liver failure, and hepatocellular carcinoma. Despite efforts to control transmission through vaccination and public health interventions, hepatitis B and C infections remain significant public health challenges worldwide, particularly in low- and middle-income countries with high prevalence rates. The rising incidence of hepatitis B and C infections drives demand for accurate and accessible diagnostic tests to facilitate early detection, surveillance, and treatment monitoring, emphasizing the critical role of diagnostics in disease control and prevention strategies.
Hepatitis B and C Diagnostics Market Opportunity: Expansion of Screening and Testing Programs in High-Risk Populations
An opportunity for growth within the hepatitis B and C diagnostics market lies in the expansion of screening and testing programs targeting high-risk populations. Identifying individuals at risk of hepatitis B and C infections, including injection drug users, prisoners, migrants, and healthcare workers, is crucial for early diagnosis and timely intervention. By collaborating with public health agencies, healthcare providers, and community organizations, stakeholders can expand access to screening and testing services in high-risk settings, enhance awareness of hepatitis B and C infections, and facilitate linkage to care for individuals testing positive. Moreover, leveraging innovative screening strategies such as outreach programs, mobile clinics, and self-testing kits can reach underserved populations and improve diagnostic coverage, ultimately reducing the burden of hepatitis B and C infections and improving health outcomes on a global scale. Embracing this opportunity not only addresses unmet diagnostic needs but also contributes to achieving the World Health Organization's targets for hepatitis elimination by 2030.
Hepatitis B and C Diagnostics Market Share Analysis: Immunodiagnostics is the fastest growing market segment over the forecast period to 2030
In the market for Hepatitis B and C Diagnostics, the segment experiencing the fastest growth is Immunodiagnostics. Immunodiagnostics involves the detection of specific antibodies or antigens related to Hepatitis B and C viruses in patient samples. This method offers rapid and accurate diagnosis, enabling healthcare providers to initiate appropriate treatment and implement necessary preventive measures promptly. With the increasing prevalence of Hepatitis B and C infections globally, especially in regions with limited access to healthcare services, there is a growing demand for reliable diagnostic tools like immunodiagnostics. Additionally, advancements in technology have led to the development of more sensitive and specific immunodiagnostic assays, further driving the growth of this segment. As efforts to control and manage Hepatitis B and C infections intensify, the market for immunodiagnostics is expected to continue expanding rapidly.
Hepatitis B and C Diagnostics Market Segmentation
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Hepatitis B and C Diagnostics Companies
Bio Rad Laboratories Inc
bioMerieux SA
DAAN Gene Co. Ltd
DiaSorin SpA
Enzo Biochem Inc
F. Hoffmann La Roche Ltd
Grifols S.A.
Hologic Inc
MedMira Inc
OraSure Technologies Inc
PerkinElmer Inc
QIAGEN N.V.
Quidel Corp
Randox Laboratories Ltd
Siemens AG
Sysmex Corp
Xiamen Innovax Biotech Co. Ltd
* List not Exhaustive
Reasons to Buy the Hepatitis B and C Diagnostics Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Hepatitis B and C Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Hepatitis B and C Diagnostics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Hepatitis B and C Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Hepatitis B and C Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Hepatitis B and C Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Hepatitis B and C Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Hepatitis B and C Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Hepatitis B and C Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Hepatitis B and C Diagnostics Industry
4.2 Key Market Trends in Hepatitis B and C Diagnostics Industry
4.3 Potential Opportunities in Hepatitis B and C Diagnostics Industry
4.4 Key Challenges in Hepatitis B and C Diagnostics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Hepatitis B and C Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Hepatitis B and C Diagnostics Market Outlook by Segments
7.1 Hepatitis B and C Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
8 North America Hepatitis B and C Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Hepatitis B and C Diagnostics Markets in 2024
8.2 North America Hepatitis B and C Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Hepatitis B and C Diagnostics Market size Outlook by Segments, 2021-2030
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
9 Europe Hepatitis B and C Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Hepatitis B and C Diagnostics Markets in 2024
9.2 Europe Hepatitis B and C Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Hepatitis B and C Diagnostics Market Size Outlook by Segments, 2021-2030
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
10 Asia Pacific Hepatitis B and C Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Hepatitis B and C Diagnostics Markets in 2024
10.2 Asia Pacific Hepatitis B and C Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Hepatitis B and C Diagnostics Market size Outlook by Segments, 2021-2030
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
11 South America Hepatitis B and C Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Hepatitis B and C Diagnostics Markets in 2024
11.2 South America Hepatitis B and C Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Hepatitis B and C Diagnostics Market size Outlook by Segments, 2021-2030
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
12 Middle East and Africa Hepatitis B and C Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Hepatitis B and C Diagnostics Markets in 2024
12.2 Middle East and Africa Hepatitis B and C Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Hepatitis B and C Diagnostics Market size Outlook by Segments, 2021-2030
By Type
Immunodiagnostics
NAT
By Disease
Hepatitis B
Hepatitis C
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bio Rad Laboratories Inc
bioMerieux SA
DAAN Gene Co. Ltd
DiaSorin SpA
Enzo Biochem Inc
F. Hoffmann La Roche Ltd
Grifols S.A.
Hologic Inc
MedMira Inc
OraSure Technologies Inc
PerkinElmer Inc
QIAGEN N.V.
Quidel Corp
Randox Laboratories Ltd
Siemens AG
Sysmex Corp
Xiamen Innovax Biotech Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
